Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
15
×
deals
15
×
life sciences
national blog main
boston blog main
boston top stories
clinical trials
national top stories
boston
san francisco blog main
fda
san francisco top stories
startups
investing
new york blog main
alnylam pharmaceuticals
new york top stories
sanofi
alexion pharmaceuticals
hepatitis b
ipo
rna interference
roche
san diego blog main
san diego top stories
abbvie
akouos
allergan
amgen
autoimmune disorders
boehringer ingelheim
cancer
crispr
editas medicine
eli lilly
genentech
glaxosmithkline
indiana blog main
indiana top stories
melinta therapeutics
What
medicines
15
×
drug
deal
disease
new
research
therapeutics
biotech
company
fda
ipo
pharma
adds
ago
alliance
bacteria
called
cancer
candidate
developing
dicerna
gene
hepatitis
infectious
pact
pharmaceuticals
plans
potential
roche
startup
targets
team
year
years
abandoning
abbvie
acquire
acquisitions
address
affects
Language
unset
Current search:
medicines
×
biotech
×
deals
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
4 years ago
Synlogic Lands $80M from Ginkgo to Ramp Up “Living Medicines” R&D
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?